Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Manage your formulary budget
|Title:||Method for inhibiting expression of inducible nitric oxide synthase with tetracycline|
|Abstract:||The invention is a method of inhibiting the production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo biological system. The method employs a tetracycline compound to inhibit the production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the biological system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.|
|Inventor(s):||Amin; Ashok R. (Union, NJ), Abramson; Steven B. (Rye, NY), Golub; Lorne M. (Smithtown, NY), Ramamurthy; Nungavaram S. (Smithtown, NY), McNamara; Thomas F. (Port Jefferson, NY), Greenwald; Robert A. (Melville, NY), Trachtman; Howard (New Rochelle, NY)|
|Assignee:||The Research Foundation of The State University of New York (Stony Brook, NY) Hospital For Joint Diseases (New York, NY)|
1. A method of inhibiting expression of inducible nitric oxide synthase in a mammal system, comprising administering to said mammal system an amount of a tetracycline compound
sufficient to inhibit inducible nitric oxide synthase expression in said mammal system.
2. The method according to claim 1, wherein the tetracycline compound has substantially no anti-microbial activity in said mammal system.
3. The method according to claim 1, wherein the tetracycline compound has metalloproteinase inhibitory activity.
4. The method according to claim 1, wherein the tetracycline compound is 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3), 6-.alpha.-deoxy-5-hydroxy-4-dedimethylaminotetracycline (CMT-8), 4-dedimethylaminotetracycline (CMT-1), doxycycline, or minocycline.
5. The method according to claim 1, wherein said mammal system is a mammal having a condition characterized by increased nitric oxide production.
6. The method according to claim 5, wherein said mammal has nitric oxide-dependent glomerular inflammation.
7. The method according to claim 5, wherein said mammal has osteoarthritis.
8. The method according to claim 1, wherein said method further comprises providing to said mammal system an anti-inflammatory amount of a steroidal or non-steroidal anti-inflammatory drug.
9. The method according to claim 1, wherein said mammal system is a mammal having a condition characterized by an abnormally high level of activity of inducible nitric oxide synthase.
10. The method according to claim 1, wherein said mammal system is an in vitro cellular system or an ex vivo tissue or organ system wherein a measured amount of nitric oxide production is indicative of expression of inducible nitric oxide synthase.